Q3 2025 Scholar Rock Holding Corp Earnings Call Transcript
Key Points
- Scholar Rock Holding Corp (SRRK) has a strong conviction in the potential of apidogramab for treating SMA, supported by robust phase three trial data.
- The company is actively working on regulatory approval, having had a constructive Type A meeting with the FDA regarding the Bloomington facility's compliance issues.
- Scholar Rock Holding Corp (SRRK) is accelerating the development of a second fill-finish facility to ensure supply chain redundancy and mitigate risks.
- The company has strengthened its financial position by raising $141.7 million in the third quarter, extending its cash runway into 2027.
- Scholar Rock Holding Corp (SRRK) is advancing its pipeline with the initiation of the phase 2 Opal trial and plans to start clinical development for a second neuromuscular disorder.
- Scholar Rock Holding Corp (SRRK) received a complete response letter from the FDA due to compliance issues at the third-party manufacturing facility, delaying apidogramab's approval.
- The company faces operational risks associated with transitioning between manufacturing facilities, which could impact product supply.
- There is uncertainty regarding the timeline for the FDA's reinspection of the Bloomington facility, which is crucial for resubmitting the BLA.
- The potential delay in apidogramab's approval could impact the company's market entry and competitive positioning in the SMA treatment space.
- Scholar Rock Holding Corp (SRRK) may face financial challenges if further delays occur, necessitating additional financing options that could be costly.
Good morning ladies and gentlemen, and welcome to Scholar Rock's 3rd quarter 2025 conference call. At this time, all lines are in listen-only mode. Following the presentation, we will conduct a question answer session. To ask a question during the session, you will need to press 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press 11 again. This call is being recorded on Friday, November 14, 2025. I would now like to turn the conference over to Scholar Rock. Please go ahead.
Good morning. I'm Laura Eki, Vice President of investor relations at Scholarrock. With me today are David Hillel, Chairman and Chief Executive Officer, Akshay Vashna, President of R&D, Keith Wood, Chief Operating Officer, and Via Sinha, Chief Financial Officer.
For those of you participating via conference call, the accompanying slides can be accessed in the event section on the investors page of our website.
During
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
